P-Cure

P-Cure develops and supplies compact, gantry-less adaptive proton therapy solutions for cancer treatment.

Health Tech & Life Sciences
Active
Mature Shilat, Israel Founded 2007
Last updated 2026-07-26
Total raised
$36.0M
Last: Undisclosed Round 2021-02
Stage
Mature
Founded
2007
Headcount
28
HQ
Shilat, Israel
Sector
Health Tech & Life Sciences

About

P-Cure is an Israeli med-tech company founded in 2007 by Michael Marash. It specializes in image-guided proton radiation therapy for cancer treatment, aiming to make this advanced therapy more accessible and affordable. Their technology includes a 360-degree gantry-less system that allows for treatment in a seated position, reducing the size and cost of the equipment compared to traditional proton therapy systems. P-Cure's first product, P-Artis, an upright imaging system, received FDA approval in September 2016. The company's proton therapy system has also received FDA clearance for sales in the USA. P-Cure operates globally with R&D, production, and service platforms in the US, Israel, and China.

Funding history · 4 rounds · $36.0M total

2021-01
C Round $11.0M
★ Popular Line Medical
2019-06
B Round $15.0M
★ Everett Partners★ StarVest Partners★ Lions Peak Capital★ Popular Line Medical
2016-11
A Round $10.0M
★ Everett Partners★ Lions Peak Capital
1969-12
Grant Undisclosed

Headcount over time

From 15 (2018-07) to 45 (2026-03) · +30 (+200%) · 38 points · source: Finder history + radar grounding
450 2018-07 2026-03

Q&A

What is P-Cure's primary focus?
P-Cure specializes in adaptive proton therapy for cancer patients, developing an imaging-based solution for cost-effective cancer treatment using proton radiation.
When was P-Cure founded?
P-Cure was founded in January 2007.
What is P-Cure's total amount raised to date?
P-Cure has raised a total of $36,000,000 USD.
When did P-Cure complete its most recent funding round and who participated?
P-Cure completed a funding round in February 2021, with Popular Line Medical participating.
Which investors participated in P-Cure's December 2016 funding round?
In December 2016, Lions Peak Capital and Everett Partners participated in P-Cure's funding round.
What is the P-ARTIS system?
The P-ARTIS is a comprehensive and fully integrated solution from P-Cure designed to treat patients with protons, including diagnostic-quality volumetric imaging, a robotic positioning system, and real-time X-ray imaging.
Where are P-Cure's offices located?
P-Cure has offices in Shilat, Israel; Akron, OH, USA; and China.

Team · 1

Michael Marash
Founder · Founder & CEO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Machinery & RoboticsPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesHealthcareProvidersMedical Devices IndustryMedical Equipment
Business model
B2B

Highlights

1 Patents

Tags

imagingcancerct-scanx-rayoncologymedical-technologieshospitalsmedical-equipmentclinicsdoctorshealthcare-providersdiagnosticstreatmentsoptronics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitep-cure.com
LinkedInlinkedin.com/company/1870371
YouTubeyoutube.com/channel/UCRjtL4i3gLixZ7AN2tKWTWA
Wikidatawikidata.org/wiki/Q130285256

Identifiers & details

Legal nameP-Cure Ltd.
Founded2007
Employees (exact)28
OfficesChina; Akron
Wikidata QIDQ130285256

Radar intelligence

Patents

EPO22

Web history (Wayback)

Domainp-cure.com

Wikidata

QIDQ130285256

Certificate / subdomain footprint

Subdomains1

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513900860
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2006-12-06
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events5 — charge (3), annual_report (1), shares_capital (1)
Registered addressכרמל 14 שילת

Recent registry events

DateEvent
2026-05-31סילוק שעבוד
2026-05-31סילוק שעבוד
2026-05-31סילוק שעבוד
2026-04-28דו~ח שנתי-שינוי בהוראות בתקנון
2025-11-19הקצאת מניות